The Pfizer-BioNTech COVID-19 vaccine limits transmission, hospitalization, and death from COVID-19 even among patients infected by variants of the virus, but the effectiveness of antibodies it generates diminishes as patients get older, according to a study by UT Southwestern researchers.
Suggests a more proactive, innate immune response among females
University of Maryland School of Medicine researchers have identified how multiple genes of SARS-CoV-2 affect disease severity, which could lead to new ways in how we develop future vaccines or develop newer treatments. The genes control the immune system of the host, contributing to how fiercely the body responds to a COVID-19 infection.
A method that combines case investigation data from local health departments and hospitalizations records from local institutions allows for the objective detection of new waves of infection during a pandemic, according to research from UTHealth Houston.
A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.
Does COVID-19 infection affect people with epilepsy differently? Are people with epilepsy less likely to get vaccinated? A session at the European Epilepsy Congress in July 2022 covered these topics, and more.
An analysis of millions of SARS-CoV-2 genomes finds that recombination of the virus is uncommon, but when it occurs, it is most often in the spike protein region, the area which allows the virus to attach to and infect host cells.
Researchers at the University of Illinois Chicago are working with the National Institutes of Health and University of Minnesota to establish a center for antiviral drug development for pandemic-level viruses, including Ebola and SARS-CoV-2.
Protection against severe COVID-19 by two doses of Pfizer-BioNTech and AstraZeneca COVID-19 vaccines remained high up to six months after second doses, finds new research which analysed NHS health record data on over seven million adults. Reassuringly, the University of Bristol-led study published in The BMJ today [July 20], found protection in older adults aged over 65 years, and in clinically vulnerable adults.
Could the SARS-CoV-2 vaccine reawaken previous antibody responses and point the way to a universal coronavirus vaccine? A new analysis of the antibody response to a COVID-19 vaccine suggests the immune system’s history with other coronaviruses, including those behind the common cold, shapes the patient’s response, according to a recently published study published in Cell Reports.
“Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”
Rutgers scientists have developed a lab test that can quickly and easily identify which variant of the virus causing COVID-19 has infected a person, an advance expected to greatly assist health officials tracking the disease and physicians treating infected patients.
New research from the Case Western Reserve University (CWRU) School of Medicine suggests that the children younger than age 5 who are infected with the COVID-19 Omicron variant have less risk of severe health outcomes than those infected with the Delta variant.